Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Its IPO is one of several on tap for the biotech ... plus royalties of 12% to 19% of net sales. Ascentage Pharma’s Rockville hub, totaling 6,520 square feet, is its only U.S. office.

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US. Read more here.

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...